(Reuters) – Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc’s chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter results.
Source: Reuters Medical News